Nanodermatology: a bright glimpse just beyond the horizon - part I.
暂无分享,去创建一个
[1] T. Luger,et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. , 2009, Acta dermato-venereologica.
[2] S. Ständer,et al. Pregabalin in the treatment of chronic pruritus. , 2008, Journal of the American Academy of Dermatology.
[3] S. Ständer,et al. Neurophysiological and neurochemical basis of modern pruritus treatment , 2008, Experimental dermatology.
[4] J. Taverna,et al. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. , 2006, Journal of the American Academy of Dermatology.
[5] J. West,et al. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[6] Alexandru D. P. Papoiu,et al. What causes itch in atopic dermatitis? , 2008, Current allergy and asthma reports.
[7] D. Silverberg,et al. Randomised crossover trial of naltrexone in uraemic pruritus , 1996, The Lancet.
[8] Nandi Ps,et al. Recognition and management of acute pericarditis. , 1973 .
[9] Alexandru D. P. Papoiu,et al. Topical capsaicin. The fire of a ‘hot’ medicine is reignited , 2010, Expert opinion on pharmacotherapy.
[10] J. Bernhard,et al. Willan's itch and other causes of pruritus in the elderly , 2005, International journal of dermatology.
[11] R. Hickerson,et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] A. Nasir,et al. Topical botulinum toxin. , 2010, The Journal of clinical and aesthetic dermatology.
[13] Mellar P. Davis,et al. Mirtazapine for pruritus. , 2003, Journal of pain and symptom management.
[14] K. Eric Drexler,et al. Nanosystems - molecular machinery, manufacturing, and computation , 1992 .
[15] G. Yosipovitch,et al. New insights into the pathophysiology and treatment of chronic itch in patients with end‐stage renal disease, chronic liver disease, and lymphoma , 2010, International journal of dermatology.
[16] H. van Os-Medendorp,et al. Effectiveness of the nursing programme ‘Coping with itch’: a randomized controlled study in adults with chronic pruritic skin disease , 2007, The British journal of dermatology.
[17] D. Duffy,et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. , 2009, The Journal of investigative dermatology.
[18] M. Prausnitz,et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine , 2010, Gene Therapy.
[19] P. Dykes,et al. An appraisal of the methods used in the assessment of atrophy from topical corticosteroids , 1979, The British journal of dermatology.
[20] J. Ring,et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N‐palmitoylethanolamine (ATOPA study) , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.
[21] B. Gilchrest,et al. A survey of skin problems and skin care regimens in the elderly. , 1987, Archives of dermatology.
[22] A. Vaglio,et al. Gabapentin for uraemic pruritus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] T. Luger,et al. Treatment of pruritic diseases with topical calcineurin inhibitors , 2006, Therapeutics and clinical risk management.
[24] G. Yosipovitch,et al. Neuropathic and psychogenic itch , 2008, Dermatologic therapy.
[25] V Jenning,et al. Encapsulation of retinoids in solid lipid nanoparticles (SLN). , 2001, Journal of microencapsulation.
[26] K E Drexler,et al. Machine-phase nanotechnology. , 2001, Scientific American.
[27] Thomas A. Luger,et al. Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin , 2003, The Journal of Neuroscience.
[28] T. Luger,et al. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. , 2006, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[29] G. Yosipovitch,et al. Butorphanol for treatment of intractable pruritus. , 2006, Journal of the American Academy of Dermatology.
[30] J. Szepietowski,et al. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. , 2005, Acta dermatovenerologica Croatica : ADC.
[31] A. Nasir. Nanotechnology and dermatology: part I--potential of nanotechnology. , 2010, Clinics in dermatology.
[32] T. Muramatsu,et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] A. Nasir. Nanodermatology: a glimpse of caution just beyond the horizon - part II. , 2010, Skin therapy letter.
[34] G. Yosipovitch,et al. Menthol: a refreshing look at this ancient compound. , 2007, Journal of the American Academy of Dermatology.
[35] G. Freitag,et al. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. , 1997, Current medical research and opinion.
[36] Lucinda F Buhse,et al. Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[37] J. Storrs Hall,et al. Nanofuture: What's Next For Nanotechnology , 2005 .
[38] Adam J Friedman,et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. , 2009, The Journal of investigative dermatology.
[39] F. Camacho,et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients , 2009, The Journal of dermatological treatment.
[40] H. Nojima,et al. Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. , 2007, The Journal of investigative dermatology.
[41] E. Monroe. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. , 1989, Journal of the American Academy of Dermatology.
[42] A. Fleischer. Pruritus in the elderly: management by senior dermatologists. , 1993, Journal of the American Academy of Dermatology.
[43] T. Mihaljevic,et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping , 2004, Nature Biotechnology.
[44] G. Yosipovitch,et al. Therapy of pruritus , 2010, Expert opinion on pharmacotherapy.
[45] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[46] Gordon J. Wood,et al. An insatiable itch. , 2009, The journal of pain : official journal of the American Pain Society.
[47] N. Bergasa,et al. Gabapentin in patients with the pruritus of cholestasis: A double‐blind, randomized, placebo‐controlled trial , 2006, Hepatology.
[48] G. Yosipovitch,et al. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. , 2004, Journal of the American Academy of Dermatology.
[49] G. Yosipovitch,et al. Nocturnal itch: why do we itch at night? , 2007, Acta dermato-venereologica.
[50] T. Flynn. Update on botulinum toxin. , 2006, Seminars in cutaneous medicine and surgery.
[51] Han-Joo Lee,et al. Antibacterial effect of nanosized silver colloidal solution on textile fabrics , 2003 .
[52] A. Nasir. Nanotechnology in vaccine development: a step forward. , 2009, The Journal of investigative dermatology.
[53] David J. Anderson,et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms , 2009, Proceedings of the National Academy of Sciences.
[54] T. Luger,et al. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. , 2010, Journal of the American Academy of Dermatology.
[55] Linda M. Katz,et al. Nanotechnology and applications in cosmetics : General overview , 2007 .
[56] G. Yosipovitch,et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. , 2001, Journal of the American Academy of Dermatology.
[57] D. Alling,et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. , 1999, Journal of the American Academy of Dermatology.
[58] R. Norman. Xerosis and pruritus in the elderly: recognition and management. , 2003, Dermatologic therapy.
[59] A. Rush,et al. Sertraline as a first‐line treatment for cholestatic pruritus , 2007, Hepatology.